Literature DB >> 2876773

Effects of radiation on host-tumor interactions using the multicellular tumor spheroid model.

K M Wilson, E M Lord.   

Abstract

Use of the multicellular tumor spheroid as a tumor model allows separate host or tumor treatment with ionizing radiation and examination of the effects on host-tumor immune interactions. Spheroids of EMT6/Ro, a BALB/c mammary tumor were implanted into the peritoneal cavity of syngeneic immunized mice, recovered, and dissociated into single cells. Cytolytic activity of mature spheroid associated cells and peritoneal cells was resistant to radiation doses as high as 1000 rads when irradiate directly prior to assay. Mice irradiated (200, 400, 700 rads) 24 h prior to spheroid injection had an increased number of tumor cells and decreased number of tumor infiltrating and peritoneal host cells upon spheroid recovery. This was paralleled by an increased colony forming efficiency per spheroid. Cytolytic activity of the spheroid associated cells against radiolabeled EMT6 cells was in many cases decreased with radiation although lysis was the same on a per cell basis. Cytolytic activity by peritoneal cells from these mice increased with dose as measured on a per cell basis. This activity from irradiated animals was carried out by a Thy1+ cell.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876773     DOI: 10.1007/bf00205550

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  The therapeutic significance of concomitant antitumor immunity. I. LY-1-2+ T cells from mice with a progressive tumor can cause regression of an established tumor in gamma-irradiated recipients.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 2.  Selective effects of ionizing radiations on immunoregulatory cells.

Authors:  G Doria; G Agarossi; L Adorini
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

3.  The multicellular tumor spheroid model. I. Characterization of the allograft response in sensitized mice.

Authors:  E M Lord; G B Nardella; R M Sutherland
Journal:  Cell Immunol       Date:  1980-06       Impact factor: 4.868

4.  Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

Authors:  S E Ettinghausen; E H Lipford; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

5.  Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Assessment of in situ host immunity to syngeneic tumors utilizing the multicellular spheroid model.

Authors:  E M Lord; G Burkhardt
Journal:  Cell Immunol       Date:  1984-05       Impact factor: 4.868

7.  Activation of mouse lymphocytes inhibits induction of rapid cell death by x-irradiation.

Authors:  J W Lowenthal; A W Harris
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

8.  Morphological and functional characteristics of cells infiltrating and destroying tumor multicellular spheroids in vivo.

Authors:  E M Lord; D P Penney; R M Sutherland; R A Cooper
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1979-10

9.  Comparison of in situ and peripheral host immunity to syngeneic tumours employing the multicellular spheroid model.

Authors:  E M Lord
Journal:  Br J Cancer Suppl       Date:  1980-04

10.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

View more
  1 in total

1.  Specific (EMT6) and non-specific (WEHI-164) cytolytic activity by host cells infiltrating tumour spheroids.

Authors:  K M Wilson; E M Lord
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.